Core Insights - Certara, Inc. has published over 200 papers in the past year and has 11 scientists listed among the top 2% most cited researchers globally according to the 2025 Stanford/Elsevier ranking, highlighting its significant impact in pharmaceutical research [1][2][3] Company Achievements - The company has maintained its leadership in pharmacology and pharmacokinetics, with its scientists recognized for their contributions either in the calendar year 2024 or throughout their careers [3] - Amin Rostami-Hodjegan, a key figure at Certara, received the 2025 Lewis B. Sheiner Lecturer Award for his lifetime achievements in pharmacometric research [4] Technological Innovations - The Simcyp Simulator®, co-founded by Rostami-Hodjegan, is utilized by over 11 global regulatory agencies and has supported more than 120 FDA-approved drugs, demonstrating its effectiveness in drug development [4] - The Simcyp Consortium, consisting of 35 leading biopharmaceutical companies, is recognized as a global authority on mechanistic PBPK modeling and simulation [4] Industry Trends - New methodologies like the Simcyp Simulator are crucial as the biopharma industry shifts away from animal testing, a transition supported by the FDA and NIH [5] - Certara has been at the forefront of reducing animal use in pre-clinical research for the past 25 years, aligning with industry trends towards more ethical research practices [5]